Top 8 Long-Term Biotechnology Stocks to Buy

5. Avalo Therapeutics, Inc. (NASDAQ:AVTX)

EPS Growth Past 5Y: 56.49%%

EPS Growth Next 5Y: 40.60%

Number of Hedge Fund Holdings: 12

Stock Upside Potential: 89.51%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is one of the top long-term biotechnology stocks to buy. On October 17, Piper Sandler analyst Yasmeen Rahimi reaffirmed her Buy rating on Avalo Therapeutics Inc. (NASDAQ:AVTX), maintaining a price target of $48, which implies a substantial upside potential of 167.86% from the stock’s current trading levels.

The buy stance underscores confidence in Avalo’s strategic direction and pipeline progress as it makes progress in immune dysregulation therapies. The analyst’s optimism comes on the heels of recent leadership changes, strategic collaborations, and clinical pipeline development. Avalo’s focus on novel immunology targets and its ability to execute on development milestones were central to Piper Sandler’s bullish outlook.

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a biotechnology company focused on developing treatments for immune-mediated inflammatory diseases. Its lead product candidate, AVTX-009, is an anti-IL-1β antibody in a Phase 2 clinical trial for hidradenitis suppurativa (HS). The company’s pipeline also includes other assets, such as quisovalimab and AVTX-008, which are designed to modulate the immune system.